5-MeO-DBT
5-MeO-DBT, also known as 5-methoxy-N,''N-dibutyltryptamine, is a serotonin receptor modulator, and a rare substituted tryptamine derivative, which is thought to be a psychoactive substance.
Unlike many other related compounds it exhibits very low efficacy for the 5-HT2A receptor.
5-MeO-DBT was first described in the literature by Alexander Shulgin in his 1997 book TiHKAL''. It was encountered as a novel designer drug by 2019 and was assessed pharmacologically in 2023. The drug is controlled under drug analogue legislation in a number of jurisdictions.
Use and effects
In his book TiHKAL, Alexander Shulgin briefly mentioned 5-MeO-DBT and described it as a known compound with unknown activity. Relatedly, the properties and effects of 5-MeO-DBT are unknown. In any case, related drugs like dibutyltryptamine and 4-HO-DPT have been reported to yield disappointing effects.Interactions
Pharmacology
Pharmacodynamics
Based on limited evidence, 5-MeO-DBT acts as a non-selective serotonin receptor agonist with the highest potency and efficacy at the 5-HT1A receptor. It has a similar potency to 5-MeO-MiPT for this target. The substance, unlike many other substituted tryptamines, acts as a very weak and low efficacy partial agonist for the 5-HT2A receptor. Among the group of related tryptamine analogues it also displayed the lowest efficacy for the 5-HT2C receptor.5-MeO-DBT decreased locomotor activity and failed to substitute for the discriminative stimulus effects of DOM in rodent drug discrimination tests.